Key facts
- This page summarizes Christopher Posner's Form 4 filing for Cara Therapeutics, Inc. (TVRD).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Nov 2021, 08:15.
Christopher Posner - 29 Oct 2021 Form 4 Insider Report for Cara Therapeutics, Inc. (TVRD)
- Reporting relationship
- Director, Senior Advisor
- Issuer ticker
- TVRD
- Reported as of
- 29 Oct 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Nov 2021, 08:15:20 UTC
- Prior SEC filing
- 07 Jun 2021
- Next SEC filing
- 01 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christopher Posner
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Christopher Posner filed Form 4 for Cara Therapeutics, Inc. (TVRD) on 03 Nov 2021.
Change
- Previous filing in this sequence was filed on 07 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CARA
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +5,941
- Change %
- +37%
- Price
- $0.000000
- Shares after
- 22,037
- Date
- 29 Oct 2021
- Ownership
- Direct
- Footnotes
- F1
CARA
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +142,000
- Change %
- +644%
- Price
- $0.000000
- Shares after
- 164,037
- Date
- 29 Oct 2021
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CARA
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +566,000
- Change %
- Price
- $0.000000
- Shares after
- 566,000
- Date
- 29 Oct 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 566,000
- Exercise price
- $16.83
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to an Employment Agreement, dated October 29, 2021, between the Reporting Person and the Issuer, whereby the Reporting Person is employed as a Senior Advisor to the Issuer effective October 29, 2021 and as President and Chief Executive Officer of the Issuer effective November 9, 2021 (the "Employment Agreement"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs will vest in full on March 31, 2022, subject to the Reporting Person's continued service to the Issuer on such date.
Footnote F2
Represents the number of shares underlying RSUs granted to the Reporting Person pursuant to the Employment Agreement. Each RSU represents the contingent right to receive one share of common stock of the Issuer. 25% of the RSUs will vest on October 29, 2022 and the remainder will vest over the following 12 equal quarterly installments, in each case, subject to the Reporting Person's continued service to the Issuer as of each such date.
Footnote F3
25% of the shares will vest and become exercisable on October 29, 2022 and the remainder will vest over the following 12 equal quarterly installments, in each case, subject to the Reporting Person's continued service to the Issuer as of each such date. These options were granted to the Reporting Person pursuant to the Employment Agreement.